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INTRODUCTION
Prostate cancer affects an estimated 
1 million men worldwide, with >300 000 
dying from the disease each year.1 Prostate 
specific antigen (PSA) is a biomarker that is 
widely used to help detect prostate cancer 
before symptoms develop or at an early 
stage. Diagnosing prostate cancer early 
can potentially identify tumours when they 
are at an early stage and intervention might 
improve treatment options and survival; 
however, studies have suggested that PSA 
alone has poor senstivity to determine the 
presence of prostate cancer for any risk 
stratification category.2
A recent meta-analysis concluded 
that, although screening may result in a 
small absolute benefit in disease-specific 
mortality at 10 years, it does not improve 
overall mortality.3 A European trial reported 
a 27% reduction in prostate cancer mortality 
attributable to PSA testing at 13 years.4 Two 
other trials, in the US and UK, showed 
no overall mortality benefit,5,6 although 
the results might be partially explained by 
low adherence rates and contamination 
of the control group.7,8 UK guidelines 
recommend against systematic prostate 
cancer screening, instead allowing men 
aged ≥50 years to request screening on 
demand.2 US guidelines recommend ‘For 
men aged 55 to 69 years, the decision to 
undergo periodic prostate-specific antigen 
(PSA)–based screening for prostate cancer 
should be an individual one. Before deciding 
whether to be screened, men should have 
an opportunity to discuss the potential 
benefits and harms of screening with their 
clinician and to incorporate their values and 
preferences in the decision’;9 however, the 
tools to achieve this are largely unavailable 
in both the US and UK, and such shared 
decision making is seldom undertaken.8 A 
recent BMJ rapid review, which summarised 
all the available evidence on prostate cancer 
screening with PSA tests, highlighted the 
need for research to test risk-stratified 
approaches.8
In other clinical areas, such as the 
prevention of cardiovascular disease, 
guidelines have evolved from clinical 
decisions made solely on thresholds of 
cholesterol, to those made according to 
absolute risk incorporating other risk 
factors.10,11 As highlighted recently by 
Tikkinen et al, a similar risk-stratified 
approach could provide an effective 
mechanism to improve decision making for 
doctors and patients by providing realistic 
estimates of absolute risk of prostate 
cancer incorporating age, ethnic group, 
family history, and other risk factors.8 This 
could also reduce unnecessary referrals 
as it could be applied before undertaking 
further investigations, such as magnetic 
resonance imaging (MRI) or biopsies.7,12 
A systematic review identified several 
studies deriving risk equations for 
predicting absolute risk of prostate cancer 
incorporating PSA, although the sample 
sizes were small and not representative of 
primary care; the populations studied were 
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Diagnosis of prostate cancer at an early stage 
can potentially identify tumours when intervention 
may improve treatment options and survival.
Aim
To develop and validate an equation to predict 
absolute risk of prostate cancer in asymptomatic 
men with prostate specific antigen (PSA) tests in 
primary care.
Design and setting
Cohort study using data from English general 
practices, held in the QResearch database.
Method
Routine data were collected from 1098 
QResearch English general practices linked to 
mortality, hospital, and cancer records for model 
development. Two separate sets of practices were 
used for validation. In total, there were 844 455 
men aged 25–84 years with PSA tests recorded 
who were free of prostate cancer at baseline 
in the derivation cohort; the validation cohorts 
comprised 292 084 and 316 583 men. The primary 
outcome was incident prostate cancer. Cox 
proportional hazards models were used to derive 
10-year risk equations. Measures of performance 
were determined in both validation cohorts.
Results
There were 40 821 incident cases of prostate 
cancer in the derivation cohort. The risk equation 
included PSA level, age, deprivation, ethnicity, 
smoking status, serious mental illness, diabetes, 
BMI, and family history of prostate cancer. The risk 
equation explained 70.4% (95% CI = 69.2 to 71.6) 
of the variation in time to diagnosis of prostate 
cancer (R 2) (D statistic 3.15, 95% CI = 3.06 to 3.25; 
Harrell's C-index 0.917, 95% CI = 0.915 to 0.919). 
Two-step approach had higher sensitivity than a 
fixed PSA threshold at identifying prostate cancer 
cases (identifying 68.2% versus 43.9% of cases), 
high-grade cancers (49.2% versus 40.3%), and 
deaths (67.0% versus 31.5%).
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The risk equation provided valid measures 
of absolute risk and had higher sensitivity for 
incident prostate cancer, high-grade cancers, and 
prostate cancer mortality than a simple approach 
based on age and PSA threshold.
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predominantly White, discrimination was 
limited, and calibration poorly reported.13 
Existing calculators have been designed 
to predict risk of a current diagnosis of 
prostate cancer, rather than the future 
risk of developing prostate cancer and/or 
clinically significant disease over a 10-year 
period.14–16
Currently, the decision in most primary 
care practices to refer men who are 
asymptomatic is based on binary PSA 
thresholds, although this can lead to too 
many false-negative and false-positive 
results.17 Furthermore, a binary threshold 
does not give any indication for the patient 
as to their absolute risk of developing 
prostate cancer and/or clinically significant 
disease requiring immediate intervention. 
As the diagnostic pathway has evolved 
considerably — at least in the UK and 
Europe — PSA level alone no longer triggers 
prostate biopsy; this is now preceded by 
a multiparametric MRI (mpMRI) scan. 
However, mpMRI misses approximately 
15% of important prostate cancers (Gleeson 
grade 2–5) and is difficult to interpret in 
younger men.18 
The authors aimed to develop and 
determine the additional predictive utility of 
a new algorithm to predict risk of prostate 
cancer for use in primary care in men who 
are asymptomatic. The intended use is to 
provide a better evidence base for the GP 
and patient to improve decision making 
regarding the most appropriate action, for 
example, reassurance, repetition of PSA 
test, referral for MRI, regular monitoring, 
referral to a urologist, or use of preventative 
interventions should any become available.
METHOD
Study design, data sources, and sample
The authors undertook a large open cohort 
study of men registered with 1503 practices 
contributing to the QResearch database 
(version 43), which is the largest and most 
representative GP research database in 
the UK.19 Three-quarters of practices were 
randomly allocated to the derivation dataset 
(validation cohort A) and the remaining 
quarter to a validation dataset. A second 
validation cohort (validation cohort B) of 
men registered with general practices 
contributing to the Clinical Practice 
Research Datalink (CPRD GOLD) was also 
identified.
The cohorts included men aged 
25–84 years who were registered with 
practices in the study period (1 January 1998 
to 31 March 2018 for QResearch and 
1 January 1998 to 31 March 2015 for CPRD) 
and had at least one PSA test result. Men 
with a previous diagnosis of prostate 
cancer were excluded at baseline and, as 
the aim was to quantify risk in men who 
were asymptomatic, also excluded were 
those with recorded evidence of lower 
urinary tract symptoms, including urinary 
retention, urinary frequency, nocturia, 
erectile dysfunction, haematuria, and 
haematospermia in the 28 days prior to a 
PSA test — these men were unlikely to be 
having PSA tests for screening purposes.
An initial entry date to the cohort was 
determined for each patient, which was the 
latest of the following: 
• 25th birthday; 
• date of registration with the practice plus 
1 year; 
• date on which the practice computer 
system was installed plus 1 year; or 
• the beginning of the study period 
(1 January 1998). 
The date of the first PSA test during the 
study period after the individual’s initial 
entry date was then determined; this date 
was used as the study entry date for the 
main analysis. Patients were followed up 
until the earliest of the following dates: 
• date of diagnosis of prostate cancer; 
• death; 
• de-registration with the practice; or
• last upload of computerised data and 
the study end date (31 March 2018 for 
QResearch or 31 March 2015 for CPRD 
GOLD). 
How this fits in 
Earlier diagnosis of prostate cancer could 
potentially identify tumours at a stage when 
interventions could help improve treatment 
options and survival rates. A new equation to 
predict the absolute risk of prostate cancer 
in asymptomatic men with prostate specific 
antigen (PSA) tests has been developed by 
the authors and validated externally. The 
risk equation provides a valid measure of 
absolute risk of prostate cancer, which is 
more efficient at identifying incident cases 
of prostate cancer, high-grade cancers, and 
prostate cancer deaths than an approach 
based on a simple PSA threshold. The 
prostate cancer risk model has the potential 
to prioritise patients in primary care for 
further investigation, including imaging 
by multiparametric magnetic resonance 
imaging.
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All relevant patients on the database 
were used to maximise the power and 
generalisability of the results.
Outcomes
The primary outcome measure was 
incident diagnosis of prostate cancer 
during follow-up, as recorded on the 
general practice computer records or the 
linked Hospital Episodes Statistics (HES) 
database, mortality, or cancer registry data 
(where available). For mortality, men were 
included as having the primary outcome 
where prostate cancer was recorded as the 
main cause of death. The earliest recorded 
date of prostate cancer on any of these data 
sources was used as the outcome date. 
Secondary outcomes were mortality due 
to prostate cancer and high-grade prostate 
cancer, as determined by the Gleason score 
in which ‘high grade’ constituted a recorded 
combined score of 7 (4+3), 8, 9, or 10 
(Gleason grade group 3, 4, or 5).20
Predictor variables 
The selected variables were those previously 
found to be predictive of prostate cancer 
(age, self-assigned ethnicity, material 
deprivation [Townsend score], body mass 
index [BMI], smoking status, type 1 and 
type 2 diabetes, serious mental illness, 
and family history of prostate cancer)21 and 
recorded in patients’ primary care electronic 
records, as well as PSA levels. The latest 
information recorded in the GP record on or 
before the study entry date (that is, the date 
of the individual’s first PSA test) was used.
Derivation and validation of the models 
A risk prediction equation for prostate cancer 
diagnosis was developed and validated using 
established methods.22–24 The initial analysis 
was based on patients with complete data. 
Multiple imputation with chained equations 
was then used to replace missing values 
for BMI and smoking status for the main 
analyses.25–27 Cox’s proportional hazards 
models were used to estimate the coefficients 
for each predictor variable, with Rubin’s 
rules28 used to combine the results across 
the five imputed datasets.
Fractional polynomials29 were used to 
model non-linear risk relationships with 
continuous variables (age, BMI, and PSA 
level). Interactions between predictor 
variables and age were examined and 
significant interactions included. The 
regression coefficients from the final risk 
equation were used as weights, which were 
combined with non-parametric estimates 
of the baseline survivor function30 evaluated 
for each year up to 15 years to derive risk 
equations.31 This enabled risk estimates to 
be derived for each year of follow-up, with 
a specific focus on 10-year risk estimates. 
Validation of the model
Multiple imputation was used in both 
validation cohorts to replace missing values 
for BMI and smoking status. The final risk 
equation was then applied to both validation 
cohorts and measures of discrimination 
were calculated. As in previous studies,32 
D statistics,33 R 2,34 and Harrell’s C-statistic 
evaluated at 10 years were calculated. 
Calibration was assessed by comparing the 
mean predicted risks at 10 years with the 
observed risks, by tenth of predicted risk. 
Calibration slopes were also calculated, 
along with discrimination measures for the 
secondary outcomes of prostate cancer 
mortality and high-grade cancer.
Risk-stratified approach 
To compare performance of the new 
risk-prediction tool with current UK 
recommendations,2 the sensitivity values 
for two different strategies for classifying 
men as high risk of prostate cancer 
were calculated (Figure 1). The number 
Select for referral based on PSA
results ≥3 ng/mL,
n = 82 809 
(17.9% of 461 586)
Men with prostate cancer diagnosed
over next 10 years,
n = 7137 
(43.9% of all prostate cancer diagnoses)
Prostate cancer deaths,
n = 1132
(31.5% of all prostate cancer deaths)
high-grade Gleason score,
n = 3862
(40.3% of all high-grade Gleason score)
STRATEGY 1
Select for PSA test using age
criteria 50–69 years,
n = 461 586 
(24.9% of 1 857 408)
Select for referral based on
10-year risk of prostate cancer
including PSA ≥12.5%,
n = 83 135 
(18.0% of 461 858)
Men with prostate cancer diagnosed
over next 10 years,
n = 11 085 
(68.2% of all prostate cancer diagnoses)
Prostate cancer deaths,
n = 2404
(67.0% of all prostate cancer deaths)
high-grade Gleason score,
n = 4713
(49.2% of all high-grade Gleason score)
STRATEGY 2
Select for PSA test using risk model
without PSA to identify those with
10-year risk of prostate cancer ≥2.2%,
n = 461 858 
(24.9% of 1 857 408)
All men aged 25–84 years free of prostate cancer,
n = 1 857 408
Figure 1. Comparison of two strategies for identifying 
men at high risk of prostate cancer using the 
QResearch validation cohort. PSA = prostate specific 
antigen.
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and proportion of all cases of diagnosed 
prostate cancer that would be identified 
over 10 years in the resulting high-risk 
groups (sensitivity) were then ascertained. 
The proportion of total prostate cancer 
deaths and the proportion of high-grade 
cancer cases identified by each strategy 
were also calculated. 
Stata (version 16) was used for all 
analyses, and the TRIPOD statement for 
reporting35 was adhered to.
RESULTS
Study population and incidence rates
Overall, 1457 QResearch practices (96.9%) 
were included. Of these, 1098 were 
randomly assigned to the derivation cohort 
with the remainder (n = 359) assigned 
to a validation cohort. There were 357 
practices in the CPRD GOLD validation 
cohort. Figure 2 shows the flow of patients 
resulting in 844 455 men in the QResearch 
derivation cohort, 292 084 in the QResearch 
validation cohort, and 316 583 in the CPRD 
GOLD validation cohort.
Table 1 shows the baseline characteristics 
of men in the derivation cohort and 
both validation cohorts. In the derivation 
cohort, the median age was 57 years. 
Supplementary Table S1 shows the crude 
incidence rates for prostate cancer in 
the QResearch derivation and validation 
cohorts. There were 40 821 men diagnosed 
with prostate cancer in the QResearch 
derivation cohort; of these, 3246 (8.0%) 
died due to prostate cancer, 11 210 (27.5%) 
had a high-grade Gleason score, 14 851 
(36.4%) had a low-grade Gleason score, 
and 14 760 (36.2%) did not have a Gleason 
score recorded. The distribution was similar 
in both validation cohorts (data not shown). 
Predictor variables
Table 2 shows hazard ratios (HRs) for men 
for both the complete case analysis and the 
multiply imputed data. The final equation 
included PSA level, age, deprivation score, 
ethnicity, BMI, smoking status, family history 
of prostate cancer, serious mental illness, 
and type 1 and type 2 diabetes. Increasing 
deprivation was associated with lower risk 
of prostate cancer. Black Carribean and 
Black African men had increased adjusted 
hazard ratios compared with the White/
not recorded group. There were significant 
interactions between age and family history 
of prostate cancer, and between age 
and PSA levels; the adjusted HRs for the 
fractional polynomial terms for age, BMI, 
Figure 2. Patient selection process for QResearch 
derivation, QResearch validation, and CPRD GOLD 
validation cohorts. CPRD GOLD = Clinical Practice 
Research Datalink Global Initiative for Chronic 
Obstructive Lung Disease. PSA = prostate specific 
antigen.
All men in QResearch derivation cohort,
aged 25–84 years between
1 January 1998 and 31 March 2018,
n = 5 392 796
Excluded as existing
diagnosis of prostate cancer,
n = 33 558
Included in
derivation cohort A,
n = 5 359 238
Excluded as no PSA test
in study period,
n = 4 443 449
Excluded as lower urinary
tract symptoms in 28 days
prior to PSA,
n = 71 334
PSA test undertaken
in study period,
n = 915 789
Included in QResearch
derivation cohort B,
n = 844 455
All men in CPRD validation cohort,
aged 25–84 years between
1 January 1998 and 31 March 2015,
n = 1 846 076
Excluded as existing




n = 1 838 550
Excluded as no PSA test
in study period,
n = 1 487 334
Excluded as lower urinary
tract symptoms in 28 days
prior to PSA,
n = 34 633
PSA test undertaken
in study period,
n = 351 216
Included in CPRD
validation cohort B,
n = 316 583
All men in QResearch validation cohort,
aged 25–84 years between
1 January 1998 and 31 March 2018,
n = 1 866 939
Excluded as existing




n = 1 857 408
Excluded as no PSA test
in study period,
n = 1 540 903
Excluded as lower urinary
tract symptoms in 28 days
prior to PSA,
n = 24 421
PSA test undertaken
in study period,
n = 316 505
Included in QResearch
validation cohort B,
n = 292 084
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and PSA, as well as interaction terms, are 
shown in Supplementary Figures S1a–S1e. 
Validation 
The model had high levels of explained 
variation and discrimination in both 
validation cohorts (Table 3). In the 
QResearch validation cohort, the model 
explained 70.4% of the variation in time 
to diagnosis of prostate cancer (R 2), the D 
statistic was 3.15, and Harrell’s C-statistic 
was 0.917. For prostate cancer death, R 2 
was 66.2%, the D statistic was 2.86, and 
Harrell’s C-statistic was 0.907. For high-
grade cancer, these values were as follows: 
R 2 = 66.7%, D statistic = 2.90, and Harrell’s 
C-statistic = 0.935. The corresponding 
figures in the CPRD validation cohort are 
shown in Table 3. 
Supplementary Figure S2 shows how 
discrimination varied across practices in the 
QResearch and CPRD validation cohorts.
The calibration slope was 1.03 (95% 
CI = 1.02 to 1.04) for the CPRD validation 
cohort and 0.99 (95% CI = 0.98 to 1.01) 
for the QResearch validation cohort. 
Supplementary Figure S3 shows that the 
equation is well calibrated overall and in 
each subgroup. 
Supplementary Table S2 shows the 
sensitivity, specificity, and observed 10-year 
risk based on tenths of predicted 10-year 
risk of prostate cancer diagnosis in the 
QResearch validation cohort; as an example, 
in the top tenth of risk (that is, men with 
a 10-year predicted risk of ≥20.1%), the 
sensitivity was 65.5%, specificity 92.6%, and 
observed risk was 36.7%. 
Risk stratification and clinical use
Figure 1 compares two strategies for 
identifying men at high risk of prostate 
cancer using the QResearch validation 
cohort. The two-step approach (strategy 2) 
had higher sensitivity than the fixed PSA 
threshold (strategy 1) at identifying prostate 
cancer cases (identified 68.2% versus 43.9% 
of cases), high-grade cancers (49.2% versus 
40.3%), and deaths (67.0% versus 31.5%).
Supplementary Figure S4 shows the 
web calculator with clinical examples to 
demonstrate how the risk model could be 
used in a consultation. A 35-year-old Black 
Caribbean man with a PSA level of 3 ng/mL 
without a family history of prostate cancer 
has a 6.7% risk of developing prostate 
cancer over the next 10 years. With a family 
history of prostate cancer, his 10-year risk 
of prostate cancer would be 38.2%.
DISCUSSION
Summary
The QResearch database was used to 
develop the prostate cancer risk model in 
men who were asymptomatic. The model 
was then externally validated using two 
separate validation cohorts. The analyses 
included 1.45 million men from UK primary 
care over a 20-year period. The results 
show that the risk equation provides a 
valid measure of absolute risk and is more 
efficient at identifying incident cases of 
prostate cancer, high-grade cancers, and 
prostate cancer deaths than an approach 
based on a PSA threshold. A publicly 
available calculator has been developed to 
implement the algorithm that can be used 
Table 1. Baseline characteristics of men aged 25–84 years and free 
of prostate cancer and recent urinary symptoms at baseline
 QResearch QResearch CPRD validation 
 derivation cohort, validation cohort, cohort, 
Characteristic n (%)a n (%)a n (%)a
Total number of men, n 844 455 292 084 316 583
Median age, years (IQR) 57 (48–67) 57 (48–67) 58 (49–67)
Level of deprivation, mean Townsend –0.5 (3.1) –0.4 (3.1) –1.2 (3.0) 
 score (SD)
Age group, years
 25–49 244 480 (29.0) 83 294 (28.5) 85 087 (26.9)
 50–59 225 655 (26.7) 79 029 (27.1) 89 633 (28.3)
 60–69 211 355 (25.0) 72 989 (25.0) 81 253 (25.7)
 70–84 162 965 (19.3) 56 772 (19.4) 60 610 (19.1)
Ethnic group
 Ethnicity recorded 661 354 (78.3) 228 664 (78.3) 155 947 (49.3)
 White/not recorded 763 692 (90.4) 264 163 (90.4) 305 087 (96.4)
 Indian 15 883 (1.9) 5428 (1.9) 2693 (0.9)
 Pakistani 9501 (1.1) 3087 (1.1) 1012 (0.3)
 Bangladeshi 4875 (0.6) 2003 (0.7) 254 (0.1)
 Other Asian 8388 (1.0) 2642 (0.9) 1311 (0.4)
 Black Caribbean 13 198 (1.6) 4354 (1.5) 1644 (0.5)
 Black African 12 631 (1.5) 4704 (1.6) 1750 (0.6)
 Chinese 1968 (0.2) 667 (0.2) 293 (0.1)
 Other ethnic group 14 319 (1.7) 5036 (1.7) 2539 (0.8)
Smoking status
 Smoking status recorded 839 482 (99.4) 290 479 (99.5) 314 742 (99.4)
 Non-smoker 421 809 (50.0) 144 973 (49.6) 132 363 (41.8)
 Ex-smoker 250 843 (29.7) 86 556 (29.6) 78 345 (24.7)
 Light smoker (1–9/day) 96 515 (11.4) 34 647 (11.9) 51 075 (16.1)
 Moderate smoker (10–19/day) 36 412 (4.3) 12 709 (4.4) 30 271 (9.6)
 Heavy smoker (≥20/day) 33 903 (4.0) 11 594 (4.0) 22 688 (7.2)
Medical history
 Median PSA level, score (IQR) 1.18 (1.82) 1.16 (1.76) 1.22 (2.09)
 BMI recorded 672 319 (79.6) 234 612 (80.3) 237 333 (75.0)
 Mean BMI, kg/m2 (SD) 27.2 (4.4) 27.2 (4.4) 26.7 (4.0)
 Family history of prostate cancer 8881 (1.1) 2884 (1.0) 1999 (0.6)
 Serious mental illness 6475 (0.8) 2386 (0.8) 1946 (0.6)
 Type 1 diabetes 2652 (0.3) 890 (0.3) 849 (0.3)
 Type 2 diabetes 65 406 (7.7) 23 070 (7.9) 18 512 (5.8)
aUnless otherwise stated. BMI = body mass index. CPRD = Clinical Practice Research Datalink. IQR = interquartile 
range. PSA = prostate specific antigen. SD = standard deviation.
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to communicate levels of risk to patients to 
aid shared decision making. 
Strengths and limitations 
A key strength of the study is the use of 
a large primary care database making it 
substantially larger and more representative 
of the general population than previous 
studies. Other key strengths include: 
duration of follow-up and lack of selection, 
recall, and responder bias. UK general 
practices have good levels of accuracy 
and completeness in recording clinical 
diagnoses and investigations,36 and this will 
allow the risk equation to be updated as 
data changes over time. The methods used 
to derive and validate these models are 
established approaches as used for other 
risk-prediction equations derived from the 
QResearch database.37–39 
Limitations of the study include the lack of 
formal adjudication of diagnoses of prostate 
cancer, although the authors used multiple 
linked data sources. In addition, there was 
a potential under-ascertainment of family 
history of prostate cancer or high-grade 
Gleason scores, as not all patients had 
recorded values. There may also have been 
some patients in the study cohorts who had 
undiagnosed prostate cancer. Nonetheless, 
these limitations are likely to also occur in 
the clinical setting, where the results are 
likely to be used and, hence, have a face 
validity. 
Comparison with existing literature
The HRs for established predictors were 
similar to those reported elsewhere: family 
history of prostate cancer was associated 
Table 2. Adjusted hazard ratios (95% CI) for prostate cancer 
diagnosis for the complete case analysis (n = 661 354) and analysis 
based on multiply imputed data (n = 844 455 with five imputed 
datasets)a 
 Complete case analysis Imputed data
Variable Unadjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI)
Deprivation score five-unit 0.83 (0.82 to 0.85) 0.91 (0.89 to 0.93) 0.91 (0.90 to 0.93) 
increaseb
Ethnic group
 White/not recorded 1.00 1.00 1.00
 Indian 0.40 (0.36 to 0.45) 0.67 (0.59 to 0.75) 0.67 (0.60 to 0.75)
 Pakistani 0.29 (0.24 to 0.35) 0.54 (0.45 to 0.64) 0.54 (0.46 to 0.65)
 Bangladeshi 0.16 (0.12 to 0.23) 0.46 (0.33 to 0.65) 0.47 (0.33 to 0.66)
 Other Asian 0.33 (0.29 to 0.40) 0.59 (0.50 to 0.71) 0.60 (0.50 to 0.72)
 Black Caribbean 1.54 (1.44 to 1.65) 1.56 (1.46 to 1.67) 1.56 (1.46 to 1.67)
 Black African 0.80 (0.73 to 0.88) 1.13 (1.02 to 1.25) 1.14 (1.04 to 1.26)
 Chinese 0.50 (0.37 to 0.67) 0.54 (0.40 to 0.72) 0.55 (0.41 to 0.73)
 Other ethnic group 0.74 (0.68 to 0.82) 1.09 (0.99 to 1.20) 1.10 (1.00 to 1.21)
Smoking status
 Non-smoker 1.00 1.00 1.00
 Ex-smoker 1.02 (1.00 to 1.05) 1.01 (0.98 to 1.03) 1.00 (0.98 to 1.03)
 Light smoker 0.86 (0.83 to 0.89) 0.97 (0.94 to 1.01) 0.98 (0.95 to 1.02)
 Moderate smoker 0.77 (0.72 to 0.82) 0.93 (0.88 to 0.99) 0.93 (0.88 to 0.99)
 Heavy smoker 0.74 (0.69 to 0.79) 0.94 (0.88 to 1.00) 0.95 (0.90 to 1.01)
Medical history
 Family history of prostate 1.47 (1.34 to 1.61) 1.73 (1.55 to 1.92) 1.83 (1.66 to 2.02) 
  cancerc
 Serious mental Illnessd 0.52 (0.44 to 0.63) 0.67 (0.56 to 0.80) 0.67 (0.57 to 0.79)
 No diabetes 1.00 1.00 1.00
 Type 1 diabetes 0.35 (0.25 to 0.49) 0.74 (0.53 to 1.04) 0.78 (0.58 to 1.05)
 Type 2 diabetes 0.78 (0.75 to 0.82) 0.90 (0.86 to 0.95) 0.90 (0.86 to 0.94)
aModel also includes fractional polynomial terms for age (age–0.5, age–0.5ln[age]) and BMI [BMI –1, BMI –0.5], and PSA 
(PSA–1, PSA–0.5) with interaction terms between age terms and family history, and between age and PSA terms. 
bIncreasing Townsend scores indicate increasing levels of deprivation. cInteraction with age; HR evaluated at mean 
age. dCompared with patients without this characteristic. HR = hazard ratio.
Table 3. Performance of the risk model to predict prostate cancer time to diagnosis, prostate cancer death, 
and high-grade prostate cancer in the QResearch validation and CPRD validation cohorts
 QResearch validation cohort CPRD validation cohort
 Complete data Imputed data Complete data Imputed data 
 (n = 188 013), (n = 292 084), (n = 120 869), (n = 316 583), 
 estimate (95% CI) estimate (95% CI) estimate (95% CI) estimate (95% CI)
Prostate cancer time to diagnosis    
 Harrell’s C-statistic 0.920 (0.917 to 0.923) 0.917 (0.915 to 0.919) 0.922 (0.919 to 0.925) 0.916 (0.914 to 0.918)
 D statistic 2.71 (2.67 to 2.75) 3.15 (3.06 to 3.25) 2.83 (2.78 to 2.87) 2.82 (2.79 to 2.85)
 R 2  63.7 (62.8 to 64.5) 70.4 (69.2 to 71.6) 65.6 (64.5 to 66.7) 65.5 (65.1 to 65.9)
Prostate cancer death    
 Harrell’s C-statistic  0.909 (0.895 to 0.923) 0.907 (0.897 to 0.917) 0.901 (0.865 to 0.937) 0.906 (0.894 to 0.918)
 D statistic 2.84 (2.69 to 2.99) 2.86 (2.76 to 2.97) 3.10 (2.78 to 3.42) 3.16 (3.04 to 3.28)
 R 2  65.9 (63.4 to 68.3) 66.2 (64.6 to 67.8) 69.6 (64.8 to 73.6) 69.4 (68.8 to 72.0)
High-grade prostate cancer    
 Harrell’s C-statistic  0.934 (0.930 to 0.939) 0.935 (0.932 to 0.938) — —
 D statistic 2.88 (2.82 to 2.95) 2.90 (2.85 to 2.95) — —
 R 2  66.5 (65.3 to 67.7) 66.7 (65.9 to 67.6) — —
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with a higher risk of prostate cancer, as 
in other studies,40 and Black African and 
Black Caribbean men had significantly 
higher risks compared with White men.41 
Serious mental illness was associated with 
a lower risk of prostate cancer compared 
with not having serious mental illness, as 
reported elsewhere.42 Diabetes was also 
associated with a lower risk of prostate 
cancer compared with not having diabetes, 
in line with previous studies;43,44 this has 
been postulated as being either a detection 
bias or a possible protective association of 
diabetes medication.45
The risk prediction tool outlined in the 
study presented here improved on the 
Prostate Cancer Prevention Trial14 and 
European Randomized study of Screening 
for Prostate Cancer15,16 calculators as it: 
• was developed from a large, representative 
primary care population including almost 
1.45 million men, compared with trial 
populations of several thousand men 
already selected for biopsy; 
• included established risk factors; 
• can be used to predict short-term and 
longer-term absolute risks; 
• used existing information from electronic 
health records and, as such, can be easily 
implemented in a primary care setting; 
• can be updated in line with changes in 
the population, clinical data, and clinical 
practice; and
• has been externally validated. 
In addition, the equation has been 
published for transparency. 
Implications for research and practice
The authors have developed and externally 
validated a risk equation to quantify 10-year 
risk of prostate cancer in men who are 
asymptomatic and undergoing a PSA test. 
This warrants further research to assess 
utility of the model to prioritise men in 
primary care for further investigation, such 
as mpMRI. Further research is needed 
to assess how best to implement the 
algorithm, and evaluate cost-effectiveness 
and the impact on prostate cancer diagnosis 
and subsequent survival.
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